The Latest Breaking News from Pfizer

The FDA approved Moderna's RSV vaccine, allowing the biotech to launch its second-ever product. But Moderna stock retreated.

A Pfizer medicine has been shown to greatly reduce cancer progression and improve survival outcomes for people in the advanced stages of a form of lung cancer, results published Friday showed.

While the U.S. Food and Drug Administration (FDA) and the officials from the CDC continue to investigate the risks, the current recommendation is to continue the vaccine as "the estimated benefits of RSV vaccination continued to outweigh potential risks."

CDC reports increased Guillain-Barre syndrome cases in older adults post-RSV vaccination, emphasizing benefits outweigh risks.

Reports of a rare nervous system disorder are “more common than expected” in older U.S. adults who got the new RSV vaccines

Moderna stock seesawed Thursday after confirming the U.S. government is nearing a deal to fund its pandemic bird flu vaccine.

The pharma sector is primed for solid growth owing to technological advancements, growing healthcare needs, and a rise in chronic diseases. Given this backdrop, let’s analyze the fundamentals of pharmaceutical stocks Pfizer (PFE) and Bristol-Myers Squibb (BMY) to determine which of these stocks offer better dividend stability and growth. Read…

The former pharma laggard is in a race with Shell to be the first FTSE 100 stock to be valued at £200bn

Amid healthcare’s enduring importance and increasing demand for its products and services, here are five dividend-paying healthcare stocks to consider now.

Moderna stock toppled Friday after the FDA delayed an approval decision on its RSV vaccine until the end of the month.

Pfizer's gene therapy trial for Duchenne muscular dystrophy resulted in a young patient's death from cardiac arrest